20157317IMMUNOLOGICALJOURNALVol.31No.7Jul.2015:863(2012AA02A401):300457,(,);300457,(,,,)*:,Tel:022-25616001,E-mail:tao.zhu@cansinotech.com··[]1000-8861(2015)07-0580-05;[DOI]10.13431/j.cnki.immunol.j.20150124,,,*[],。(AP)、(PTAH)(AH),。,NIH,ELISA。(FHA)≥95%,(PT)、(PRN)、(DT)(TT)。PT:AP/AHPTAH/;FHA:AP/PTAH-3/AHPTAH-2/PTAH-3>;PRN:PTAH/AP/AH>;DT:AP>PTAH>AH>;TT:PTAHAH/AP/。(DT),。[];;;[]R392.11[]AEffectsofthetypeandadsorptionstrengthofaluminumadjuvantontheimmunogenicityoftheadsorbeddiphtheria,tetanusandacellularpertussiscombinedvaccineHANLu1,2,SHAOZhongqi2,SIWeixue2,ZHUTao1,2,*1.CollegeofBiologicalEngineering,TianjinUniversityofScienceandTechnology,Tianjin300457,China;2.TianjinCansinoBiotechIncorporation,Tianjin300457,China*CorrespondingAuthor:ZHUTao,E-mail:tao.zhu@cansinotech.com[Abstract]Toinvestigatetheeffectofthetypeandadsorptionstrengthofaluminumadjuvantontheimmunogenicityoftheadsorbeddiphtheria,tetanusandacellularpertussiscombinedvaccine(DTaP)andchoosethebestaluminumadjuvant,all5antigenswereseparatelyadsorbedontoaluminum-hydroxideadjuvant(AH),phosphate-treatedaluminum-hydroxideadjuvant(PTAH)andaluminumphosphate(AP).ThedegreesofabsorptionoftheantigensinvariousstocksolutionsweretestedbeforetheexperimentalDTaPvaccineswereprepared.NIHmicewereimmunizedintraperitoneallywiththepreparedDTcPvaccineandtheimmuneserawerecollectedforantibodytiteranalysisbyELISA.ForPT,PRN,DTandTT,thedegreeofadsorptionwasfoundtodecreasewiththeincreaseofphosphateinaluminum.TheadsorptionofFHA,however,wasmaintainedabove95%regardlessofthephosphateconcentration.Theimmunogenicitystudyshowedthattheperformanceoftheadjuvantswas:AP/AHPTAH/non-adjuvantforPT,AP/PTAH-3/AHPTAH-2/PTAH-3>non-adjuvantforFHA,PTAH/AP/AH>non-adjuvantforPRN,AP>PTAH>AH>non-adjuvantforDT,PTAHAH/AP/non-adjuvantforTT.Inconclusion,theresultsdemonstratesthatthedegreeofadsorptiondonotcorrelatetoimmunogenicityoftheantigensexceptDT,andAPprovidesthebestoverallperformanceoverotheradjuvantstestedinthestudyfortheDTaPvaccine.[Keywords]Aluminumadjuvant;DTaP;Adsorptionpercentage;Immunogenicity(PT)、(FHA)、(PRN)、(DT)(TT),、、3。、、、、,。,,,,,,580··20157317IMMUNOLOGICALJOURNALVol.31No.7Jul.2015,,TB,[1]。WHO,,《》(2010)。。Hansen,,,,Balb/c[2]。Denoel,Balb/cPT、FHA、PRN3,PT、FHA、PRNFIM()4[3]。Jiang,,,[4],,,[5]。,,、,,。11.1PT、,;95%(SDS-PAGE);5%PBS(10mmol/LPB、150mmol/LNaCl,pH7.4)。FHAPRN、,();FHA200KDa75%,98KDa95%(SDS-PAGE);PRN95%(SDS-PAGE);FHA500mmol/LNaClPBS(10mmol/LPB,pH7.4),PRN150mmol/LNaClPBS(10mmol/LPB,pH7.4),DT、(),;1500Lf/mgPN;150mmol/LNaClPBS(10mmol/LPB,pH7.0)。TT,,,;1500Lf/mgPN,PBS(10mmol/LPB、150mmol/LNaCl,pH7.0)。PTAH:AH,,;0.2、0.51.0mol/L,pH6.5;,37℃12h;,2,。[6]EDTA[7]P/Al0.14、0.380.74PTAH-1、PTAH-2PTAH-3。1.2PT、FHA、PRN、DTTT(AH、PTAH-1、PTAH-2、PTAH-3AP),,50μg/ml、50μg/ml、16μg/ml、30Lf/ml、10Lf/ml,,0.5mg/ml,,。1.3FHA、PRN、DT、TTLowry,=(1-/)×100%,PTTCA,。1.4NIH,10~12g,18~22d,SPF,。7,10。5,1。9,0.5ml/,。142。28,,ELISA,0.9%OD2.1Cutoff,。1.5JMP10,,P<0.01、P<0.05;P>0.05。22.11、1,PT、PRN、DT、TT4AH80%~93%,AP(9%~40%)。PTAH,PT、PRN、DT、TT4AH,AP,,。FHA≥95%,。2.2DTaP,581··20157317IMMUNOLOGICALJOURNALVol.31No.7Jul.2015,ELISA2,2。2.3PT2,,APAH2PT,;PTAHPT。PTAH。,PT,。2.4FHA3,,FHA。3PTAH,PTAH-3,FHA;,APFHA。2.5PRN4,PRN,PRN。,AH、PTAHAP,;、PTAH-1、PTAH-2、PTAH-31Tab1Adsorptionrateoftheantigensinthestocksolutionswithdifferentadjuvants(%)AntigenAHPTAH-1PTAH-2PTAH-3APP/Al=0P/Al=0.14P/Al=0.38P/Al=0.74P/Al=1PT92.7078.2469.8261.5240.01FHA94.8095.6195.5795.7496.10PRN80.7668.3349.1425.758.99DT86.5081.5671.3262.5117.45TT88.9679.8965.4060.8327.541Fig1Adsorptionpercentagesoftheantigensinthestocksolutionswithdifferentadjuvants25Tab2AntibodytitersinseraofmiceimmunizedbytheDTaPvaccineswithdifferentadjuvants[lg(titer)]AdjuvantsPTFHAPRNDTTTAH6.15±0.375.64±0.705.02±0.625.25±0.425.54±0.43PTAH-15.82±0.305.38±0.565.23±0.545.50±0.295.70±0.42PTAH-25.35±0.375.21±0.435.48±0.675.44±0.435.85±0.42PTAH-35.77±0.315.81±0.345.11±0.375.65±0.276.05±0.30AP6.18±0.466.05±0.564.90±0.495.85±0.355.46±0.24Non-adj.5.59±0.314.72±0.324.01±0.344.66±0.235.48±0.36Thetransverselineinthefigurerevealstheoverallmeanofallsamples,eachdotindicatesthevalueofantibodytiterofeachsample,thetransverselineinthemiddleofrhombicmeandiamondrepresentsthemeanofeachgroupofsamples,thebreadthofdiamondindicatessamplesize(10pergroupinFig2toFig6),theupanddownverticesinthedimondareconfidencelimitsof95%confidenceinterval,andthetwoshorttransverselinesonandunderthedimondshoweachgroup’sstandarddeviation.Thecorrespondingelementsinthefollowingfiguressharethesamemeaning.2PTFig2Statisticalanalysisofanti-PTantibodylevelsinmousesera3FHAFig3Statisticalanalysisofanti-FHAantibodylevelsinmousesera582··20157317IMMUNOLOGICALJOURNALVol.31No.7Jul.2015,PRN。,PRN。2.6DT5,,,DT。,APDT,PTAH,AH。,。2.7TT6,3PTAH,PTAH-2PTAH-3TT,PTAHTT。AHAP2,。3,FHAAP、PTAH、AH。FHA,,。(FHA),,,;,,,[8];,,,[9]:4。。,。(DT),。“”,,,,,PTAH-3AP。FHAAH、PTAH-3、AP,APPTAH-3AH。PT,,AHAP。PTAH-3PTAH-2TT。,,[10]。,IL-6、IL-4、IL-2,MHC-II,Th2[11-14];Nalp3,IL-4PRNFig4Statisticalanalysisofanti-PRNantibodylevelsinmousesera5DTFig5Statisticalanalysisofanti-DTantibodylevelsinmousesera6TTFig6Statisticalanalysisofanti-T